Mostrando 1 - 7 Resultados de 7 Para Buscar 'Jessica C. Sharpe (14851136)', tiempo de consulta: 0.01s Limitar resultados
  1. 1
    Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy por Amr El Zawily (14851115)

    Publicado 2025
    Otros Autores:
    Agregar a favoritos
    Guardado en:
  2. 2
    Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy por Amr El Zawily (14851115)

    Publicado 2025
    Otros Autores:
    Agregar a favoritos
    Guardado en:
  3. 3
    Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy por Amr El Zawily (14851115)

    Publicado 2025
    Otros Autores:
    Agregar a favoritos
    Guardado en:
  4. 4
    Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy por Amr El Zawily (14851115)

    Publicado 2025
    Otros Autores:
    Agregar a favoritos
    Guardado en:
  5. 5
    Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy por Amr El Zawily (14851115)

    Publicado 2025
    Otros Autores:
    Agregar a favoritos
    Guardado en:
  6. 6
    Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy por Amr El Zawily (14851115)

    Publicado 2025
    Otros Autores:
    Agregar a favoritos
    Guardado en:
  7. 7
    Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy por Amr El Zawily (14851115)

    Publicado 2025
    Otros Autores:
    Agregar a favoritos
    Guardado en:

Herramientas de búsqueda: